New Endocrine Drugs for Treatment of Advanced Breast Cancer

References

• Sakai F, Cheix F, Clavel M, et al. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 1978; 76: 219
   PubMed Web of Science ®Google Scholar
• Sutherland R L, Murphy L C. The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer 1980; 16: 1141
   PubMed Web of Science ®Google Scholar
• Pasqualini J R, Gelly C. Effect of tamoxifen derivatives on the conversion of estrone sulfate to estradiol in the MCF-7 mammary cancer cell line. Cancer Lett 1988; 40: 115
   Google Scholar
• Lønning P E, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988; 35: 685
   PubMed Web of Science ®Google Scholar
• Lønning P E, Johannessen D C, Thorsen T. Alterations in the production and clearance rate of oestrone and oestrone suphate in breast cancer patients treated with aminoglutethimide. Br J Cancer 1989; 60: 107
   PubMed Web of Science ®Google Scholar
• Lønning P E, Kvinnsland S, Thorsen T, Ueland P M. Alterations in the metabolism of estrogens during treatment with aminoglutethimide in breast cancer patients: preliminary findings. Clin Pharmacokinet 1987; 13: 353
   Google Scholar
• Lønning P E, Johannessen D C, Thorsen T, Ekse D. Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. J Steroid Biochem 1989; 33: 541
   Google Scholar
• Lee R W, Buzdar A U, Blumenschvein G R, Hortobagyi N. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer 1986; 57: 40
   Google Scholar
• Vermeulen A, Verdonck L. Sex hormone concentrations in postmenopausal women. Clin Endocrinol 1978; 9: 59
   PubMedGoogle Scholar
• Vermeulen A. The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 1976; 42: 247
   PubMed Web of Science ®Google Scholar
• Longcope C, Bourget C, Flood C. The production and aromatization of dehydroepiandrosterone in post-menopausal women. Maturitas 1982; 4: 325
   PubMed Web of Science ®Google Scholar
• Santen R J, Santner S, Davis B, Veldhuis J, Samojilik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast cancer. J Clin Endocrinol Metab 1978; 47: 1257
   PubMed Web of Science ®Google Scholar
• Goldin B R, Gorbach S. Effect of diet on the plasma levels, metabolism, and excretion of estrogens. Am J Clin Nutr 1988; 48: 787
   PubMed Web of Science ®Google Scholar
• Longcope C, Gorbach S, Goldin B, Woods M, Dwyer J, Warram J. The metabolism of estradiol; oral compared to intravenous administration. J Steroid Biochem 1985; 23: 1065
   PubMedGoogle Scholar
• O'Neill J, Elton R A, Miller W R. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J 1988; 296: 741
   PubMedGoogle Scholar
• James V HT, Reed M J, Adams E F, et al. Oestrogen uptake and metabolism in vivo. Oestrogens and the human breast. Edinburgh 22–24 Sept, 1988
   Google Scholar
• Santen R J, Manni A, Harvey H. Gonadotropin releasing hormone (GnRH) analogus for the treatment of breast and prostatic cancer. Breast Cancer Res Treat 1986; 7: 129
   PubMed Web of Science ®Google Scholar
• Williams M R, Walker K J, Turkes A, Blamey R W, Nicholson R I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 1986; 53: 629
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cantwell B, Lal A, Jeffcoate S L, Harris A L. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab 1988; 66: 677
   Google Scholar
• Rader M D, Flickinger G L, De Villa G O, Mikuta J J, Mikhail G. Plasma estrogens in postmenopausal women. Am J Obstet Gynecol 1973; 116: 1069
   PubMedGoogle Scholar
• Nissen-Meyer R, Sanner T. The excretion of oestrone, pregnanediol and pregnanetriol in breast cancer patients. II. Effects of ovariectomy, ovarian irradiation and corticosteroids. Acta Endocrinol 1963; 44: 334
   PubMedGoogle Scholar
• Harris A L, Carmichael J, Cantwell B MJ, Dowsett M. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer. Br J Cancer 1989; 59: 97
   PubMed Web of Science ®Google Scholar
• Plowman P N, Nicholson R I, Walker K J. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer 1986; 54: 903
   PubMed Web of Science ®Google Scholar
• Waxman J H, Harland S J, Coombes R C, et al. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 1985; 15: 171
   PubMed Web of Science ®Google Scholar
• Beardwell C G, Hindley A C, Wilkinson P M, St John J, Bu'lock D. Hormonal changes in postmenopausal women with breast cancer treated with trilostance and dexamethasone. Clin Endocrinol 1985; 23: 413
   PubMedGoogle Scholar
• Wouters W, De Coster R, Goeminne N, Beerens D, van Dun J. Aromatase inhibition bythe antifungal ketoconazole. J Steroid Biochem 1988; 30: 387
   PubMedGoogle Scholar
• Ayub M, Levell M J. Structure-activity relationship of the inhibition of human placental aromatase by imidazole drugs including ketoconazole. J Steroid Biochem 1988; 31: 65
   PubMedGoogle Scholar
• Mason J I, Murry B A, Olcott M, Sheets J J. Imidazole antimycotics: inhibitors of steoid aromatase. Biochem Pharmacol 1985; 34: 1087
   PubMed Web of Science ®Google Scholar
• De Coster R, Caers I, Haelterman C, Debroye M. Effect of a single administration of ketoconazole on total and physiologically free plasma testosterone and 17β-oestradiol levels in healthy male volunteers. Eur J Clin Pharmacol 1985; 29: 489
   PubMedGoogle Scholar
• Harris A L, Cantwell B MJ, Dowsett M. High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. Br J Cancer 1988; 58: 493
   PubMedGoogle Scholar
• Beardwell C G, Hindley A C, Wilkinson P M, Todd I DH, Ribeiro G G, Bu'lock D. Trilostane in the treatment of advanced breast cancer. Cancer Chemother Pharamcol 1983; 10: 158
   PubMedGoogle Scholar
• Coombes R C, Powles T J, Muindi J, et al. Trilostane therapy for advanced breast cancer. Cancer Treat Rep 1985; 69: 351
   Google Scholar
• Williams C J, Barley V, Blackledge G, et al. Multicenter study of trilostane: A new hormonal agent in advanced postmenopausal breast cancer. Cancer Treat Rep 1987; 71: 1197
   PubMedGoogle Scholar
• Harris A L, Dowsett M, Smith I E, Jeffcoate S. Hydrocortisone alone vs. hydrocortisone plus aminoglutethimide: A comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol 1984; 20: 463
   PubMedGoogle Scholar
• Harris A L, Dowsett M, Smith I E, Jeffcoate S L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer 1983; 47: 621
   PubMed Web of Science ®Google Scholar
• Samojlik E, Santen R J. Adrenal suppression with aminoglutethimide: III. Comparison of plasma Δ4- and Δ5-steroids in postmenopausal women treated for breast carcinoma. J Clin Endocrinol Metab 1978; 47: 717
   Google Scholar
• Vermeulen A, Paridaens R, Heuson J C. Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol 1983; 19: 673
   PubMed Web of Science ®Google Scholar
• Maroulis G B, Abraham G E. Ovarian and adrenal contributions to peripheral steroid levels in postmenopausal women. Obstet Gynecol 1976; 48: 150
   PubMed Web of Science ®Google Scholar
• Dowsett M, Harris A L, Stuart-Harris R, et al. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients. Br J Cancer 1985; 52: 525
   Google Scholar
• Rose D P. Postmenopausal oestrogen production and its inhibition. New aspects of breast cancer, B A Stoll. Will. Heineman Med Books Ltd, London 1982; vol 5
   Google Scholar
• Dao T L, Tan E, Brooks V. A comparative evaluation of adrenalectomy and cortisone in the treatment of advanced mammary carcinoma. Cancer 1961; 14: 1259
   Google Scholar
• Santen R J, Worgul T J, Samojlik E, et al. Randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 1981; 308: 545
   Google Scholar
• Santen R J, Worgul T J, Lipton A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann Intern Med 1982; 96: 94
   PubMed Web of Science ®Google Scholar
• Rubens R D, Tinson C L, Coleman R E, et al. Prednisone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 1988; 58: 626
   Google Scholar
• Barone R M, Shamonki I M, Siiteri P K, Judd H L. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using Δ1-testololactone. J Clin Endocrinol Metab 1979; 49: 672
   PubMed Web of Science ®Google Scholar
• Dunaif A, Longcope C, Canick J, Badger T, Crowley W F. The effects of the aromatase inhibitor Δ1-testololactone on gonadotropin release and steroid metabolism in polycystic ovarian disease. J Clin Endocrinol Metab 1985; 60: 773
   Google Scholar
• Volk H, Deupree R H, Goldenberg I S, Wilde R C, Carabas R A, Escher G C. A dose response evaluation of delta-1-testololactone in advanced breast cancer. Cancer 1974; 33: 9
   PubMed Web of Science ®Google Scholar
• Brodie A MH, Garrett W M, Hendrickson J R, Tsai-Morris C H, Marcotte P A, Robinson C H. Inactivation of aromatase in vitro by 4-hydroxy-4-adrostene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids 1981; 38: 693
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cunningham D C, Stein R C, et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306
   PubMed Web of Science ®Google Scholar
• Dowsett M, Goss P E, Powles T J, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimazation of therapeutic dose and route. Cancer Res 1987; 47: 1957
   PubMed Web of Science ®Google Scholar
• Brodie A MH, Longcope C. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy-and 4-acetoxyandrostene-3,17-dione. Endocrinology 1980; 106: 19
   PubMed Web of Science ®Google Scholar
• Goss P E, Powles T J, Dowsett M, et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 1986; 46: 4823
   PubMed Web of Science ®Google Scholar
• Cunningham D, Powles T J, Dowsett M, et al. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother Pharmacol 1987; 20: 253
   PubMed Web of Science ®Google Scholar
• Santen R J, Demers L M, Adlercreutz H, et al. Inhibition of aromatase with CGS 16949A in postmenopausal women. J Clin Endocrinol Metab 1989; 68: 99
   PubMed Web of Science ®Google Scholar
• Dowsett M, Lal A, Stein R C, Coombes R C. Dose-related endocrine study of aromatase inhibitor CGS 16949A. 13th Congr Eur Soc Med Oncol. Lugano Oct 30-Nov 1, 1988
   Google Scholar
• Samojlik E, Santen R J, Worgul T J. Plasma estrone-sulfate assessment of reduced estrogen production during treatment of metastatic breast carcinoma. Steroids 1982; 39: 497
   PubMed Web of Science ®Google Scholar
• Daly M J, Jones G W, Nicholls P J, Smith H J, Rowlands M G, Bunnett M A. Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem 1986; 29: 520
   PubMed Web of Science ®Google Scholar
• Foster A B, Jarman M, Leung C-S., et al. Analogues of aminoglutethimide: selective inhibition of aromatase. J Med Chem 1985; 28: 200
   PubMed Web of Science ®Google Scholar
• Haynes B, Griggs L J, Jarman M, Coombes R C, Lønning P E, Powles T J. Pharmacokinetics of pyridoglutethimide, a new aromatase inhibitor. 30th Ann Meeting Br Ass Cancer Res, Glasgow, April, 10–121989
   Google Scholar
• Bruynseels J, Vanderpas H, van Roy P, De Coster R, Amery W K, Janssen P AJ. R76713: aromatase blocker. Single-dose effect studies in volunteers. Sixth NC1-EORTC symposium on new drugs in cancer therapy, Amsterdam, March, 7–101989
   Google Scholar
• Furr B JA, Jordan V C. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984; 25: 127
   PubMed Web of Science ®Google Scholar
• Lipton A, Harvey H, Santen R J, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982; 42(Suppl)3434s
   Google Scholar
• Smith I E, Harris A L, Morgan M, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized trial. Br Med J 1981; 283: 1432
   PubMed Web of Science ®Google Scholar
• Witte R S, Pruitt B, Tormey D C, et al. A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrine effects. Cancer 1986; 57: 34
   Google Scholar
• Valavaara R, Pyrhonen S, Heikkinen M, et al. Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 1988; 24: 785
   PubMedGoogle Scholar
• Stamm H, Roth R, Huber H-J., et al. Preliminary data on a phase-I trial of the new antiestrogen droloxifene: tolerance, pharmacokinetics and metabolism. Contr Oncol 1986; 23: 73
   Google Scholar
• Stein R C, Dowsett M, Cunningham D C, et al. Phase I/II study of the antiestrogen, zindoxifene (D16726) in the treatment of advanced breast cancer, In document
   Google Scholar
• Wakeling A E, Bowler J. Novel antioestrogens without partial agonist activity. J Steroid Biochem 1988; 31: 645
   PubMedGoogle Scholar
• Murray R, Pitt P. Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 1985; 21: 19
   PubMedGoogle Scholar
• Stuart-Harris R, Dowsett M, Bozek T, et al. Low dose aminoglutethimide in treatment of breast cancer. Lancet 1984; 2: 604
   PubMed Web of Science ®Google Scholar
• Harris A L, Cantwell B MJ, Carmichael J, et al. Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1105
   Google Scholar